Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jul 1;37(19):1608-1616.
doi: 10.1200/JCO.19.00538. Epub 2019 May 17.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Padmanee Sharma  1 , Arlene Siefker-Radtke  1 , Filippo de Braud  2 , Umberto Basso  3 , Emiliano Calvo  4 , Petri Bono  5   6 , Michael A Morse  7 , Paolo A Ascierto  8 , Jose Lopez-Martin  9 , Peter Brossart  10 , Kristoffer Rohrberg  11 , Begoña Mellado  12 , Bruce S Fischer  13 , Stephanie Meadows-Shropshire  13 , Abdel Saci  13 , Margaret K Callahan  14   15 , Jonathan Rosenberg  14   15
Affiliations
Clinical Trial

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Padmanee Sharma et al. J Clin Oncol. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Clin Oncol. 2019 Aug 10;37(23):2094. doi: 10.1200/JCO.19.01700. J Clin Oncol. 2019. PMID: 31394051 Free PMC article. No abstract available.

Abstract

Purpose: CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO3+IPI1), or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO1+IPI3). We report on the expanded NIVO1+IPI3 cohort and extended follow-up for the NIVO3 and NIVO3+IPI1 cohorts.

Methods: Patients with platinum-pretreated mUC were enrolled in this phase I/II multicenter study to receive NIVO3, NIVO3+IPI1, or NIVO1+IPI3 until disease progression or unacceptable toxicity. Primary end point was investigator-assessed objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including duration of response.

Results: Seventy-eight patients were treated with NIVO3 (minimum follow-up, 37.7 months), 104 with NIVO3+IPI1 (minimum follow-up, 38.8 months), and 92 with NIVO1+IPI3 (minimum follow-up, 7.9 months). Objective response rate was 25.6%, 26.9%, and 38.0% in the NIVO3, NIVO3+IPI1, and NIVO1+IPI3 arms, respectively. Median duration of response was more than 22 months in all arms. Grade 3 or 4 treatment-related adverse events occurred in 21 (26.9%), 32 (30.8%), and 36 (39.1%) patients treated with NIVO3, NIVO3+IPI1, and NIVO1+IPI3, respectively. Grade 5 treatment-related pneumonitis occurred in one patient each in the NIVO3 and NIVO3+IPI1 arms.

Conclusion: With longer follow-up, NIVO3 demonstrated sustained antitumor activity alone and in combination with ipilimumab. NIVO1+IPI3 provided the greatest antitumor activity of all regimens, with a manageable safety profile. This result not only supports additional study of NIVO1+IPI3 in mUC, but demonstrates the potential benefit of immunotherapy combinations in this disease.

Trial registration: ClinicalTrials.gov NCT01928394.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
CONSORT diagram. AE, adverse event; NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
FIG 2.
FIG 2.
Best tumor change from baseline in target lesion per investigator. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
FIG 3.
FIG 3.
Progression-free survival per investigator. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; PFS, progression-free survival.
FIG 4.
FIG 4.
Overall Survival. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; OS, overall survival.
FIG A1.
FIG A1.
Objective response rate by tumor programmed death ligand 1 (PD-L1) expression (A) per investigator and (B) per blinded independent central review. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; ORR, objective response rate.
FIG A2.
FIG A2.
Percent reduction from baseline in target lesions per investigator. Horizontal reference line indicates the 30% reduction consistent with a protocol-defined criteria response. Assessments are per investigator assessment using protocol-defined criteria. Crossover patients are truncated at the crossover date. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
FIG A3.
FIG A3.
Time to and duration of response per investigator. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
FIG A4.
FIG A4.
Progression-free survival (PFS) by tumor programmed death ligand 1 (PD-L1) expression per investigator. (A) NIVO3 (nivolumab 3 mg/kg monotherapy every 2 weeks). (B) NIVO3+IPI1 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks). (C) NIVO1+IPI3 (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks).
FIG A5.
FIG A5.
Overall survival (OS) by tumor programmed death ligand 1 (PD-L1) expression. (A) NIVO3 (nivolumab 3 mg/kg monotherapy every 2 weeks). (B) NIVO3+IPI1 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks). (C) NIVO1+IPI3 (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks). NE, not estimable.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. National Comprehensive Cancer Network Bladder cancer (version 5.2018) https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
    1. Bristol-Myers Squibb: Opdivo (nivolumab) [package insert]. Princeton, NJ, Bristol-Myers Squibb, 2018.
    1. Sharma P, Baron A, Necchi A, et al. Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. Cancer Res. 2018;78(abstr CT178) - PMC - PubMed
    1. Bellmunt J, de Wit R, Vaughn DJ, et al. Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) J Clin Oncol. 2018;36(abstr 410)
    1. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757. - PubMed

Publication types

Associated data